Skip to main content
Erschienen in: Breast Cancer Research 3/2003

01.06.2003 | Commentary

Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk

verfasst von: Jenny Varley, Daniel A Haber

Erschienen in: Breast Cancer Research | Ausgabe 3/2003

Einloggen, um Zugang zu erhalten

Abstract

Germline mutations in the human checkpoint gene, hCHK2, were first identified in 1999 in cases of Li–Fraumeni syndrome. Recent studies have demonstrated that the hCHK2 1100delC mutation acts as a low-penetrance tumour suppressor gene in familial breast cancer not associated with mutations in BRCA1 or BRCA2. The present article describes the published studies on hCHK2 1100delC and addresses some of the key questions raised.
Literatur
1.
Zurück zum Zitat Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988, 48: 5358-5362.PubMed Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988, 48: 5358-5362.PubMed
2.
Zurück zum Zitat Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Morris Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell ELD, Santibanez-Koref MF: Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li–Fraumeni families. Cancer Res. 1994, 54: 1298-1304.PubMed Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Morris Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell ELD, Santibanez-Koref MF: Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li–Fraumeni families. Cancer Res. 1994, 54: 1298-1304.PubMed
3.
Zurück zum Zitat Varley JM: Germline TP53mutations and Li–Fraumeni Syndrome. Mut Res. 2003, Varley JM: Germline TP53mutations and Li–Fraumeni Syndrome. Mut Res. 2003,
4.
Zurück zum Zitat Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DCR, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA: Heterozygous germ line hCHK2 mutations in Li–Fraumeni Syndrome. Science. 1999, 286: 2528-2531. 10.1126/science.286.5449.2528.CrossRefPubMed Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DCR, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA: Heterozygous germ line hCHK2 mutations in Li–Fraumeni Syndrome. Science. 1999, 286: 2528-2531. 10.1126/science.286.5449.2528.CrossRefPubMed
5.
Zurück zum Zitat Lee SB, Kim SH, Bell DW, Wahrer DCR, Schiripo TA, Jorczak MM, Sgroi D, Garber JE, Li FP, Nichols KE, Varley JM, Godwin AK, Shannon KE, Harlow E, Haber DA: Destabilization of CHK2 by a missense mutation associated with Li–Fraumeni Syndrome. Cancer Res. 2001, 61: 8062-8067.PubMed Lee SB, Kim SH, Bell DW, Wahrer DCR, Schiripo TA, Jorczak MM, Sgroi D, Garber JE, Li FP, Nichols KE, Varley JM, Godwin AK, Shannon KE, Harlow E, Haber DA: Destabilization of CHK2 by a missense mutation associated with Li–Fraumeni Syndrome. Cancer Res. 2001, 61: 8062-8067.PubMed
6.
Zurück zum Zitat Wu X, Webster SR, Chen J: Characterization of tumor-associated Chk2 mutations. J Biol Chem. 2001, 276: 2971-2974. 10.1074/jbc.M009727200.CrossRefPubMed Wu X, Webster SR, Chen J: Characterization of tumor-associated Chk2 mutations. J Biol Chem. 2001, 276: 2971-2974. 10.1074/jbc.M009727200.CrossRefPubMed
7.
Zurück zum Zitat Rhind N, Russell P: Chk1 and Cds1: linchpins of the DNA damage and replication checkpoint pathways. J Cell Sci. 2000, 113: 3889-3896.PubMedPubMedCentral Rhind N, Russell P: Chk1 and Cds1: linchpins of the DNA damage and replication checkpoint pathways. J Cell Sci. 2000, 113: 3889-3896.PubMedPubMedCentral
8.
Zurück zum Zitat Zhou B-BS, Elledge SJ: The DNA damage response: putting checkpoints into perspective. Nature. 2000, 408: 433-439. 10.1038/35044005.CrossRefPubMed Zhou B-BS, Elledge SJ: The DNA damage response: putting checkpoints into perspective. Nature. 2000, 408: 433-439. 10.1038/35044005.CrossRefPubMed
9.
Zurück zum Zitat Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomaki K, Nevanlinna H: p53, CHK2, and CHK1 genes in Finnish families with Li–Fraumeni Syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res. 2001, 61: 5718-5722.PubMed Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomaki K, Nevanlinna H: p53, CHK2, and CHK1 genes in Finnish families with Li–Fraumeni Syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res. 2001, 61: 5718-5722.PubMed
10.
Zurück zum Zitat Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J: The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature. 2001, 410: 842-847. 10.1038/35071124.CrossRefPubMed Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J: The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature. 2001, 410: 842-847. 10.1038/35071124.CrossRefPubMed
11.
Zurück zum Zitat Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR: Low-penetrance susceptibility to breast cancer due to CHEK2 *1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002, 31: 3-4. 10.1038/ng879.CrossRef Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR: Low-penetrance susceptibility to breast cancer due to CHEK2 *1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002, 31: 3-4. 10.1038/ng879.CrossRef
12.
Zurück zum Zitat Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K, Blomqvist C, Bartek J, Kallioniemi O-P, Nevanlinna H: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002, 71: 432-438. 10.1086/341943.CrossRefPubMedPubMedCentral Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K, Blomqvist C, Bartek J, Kallioniemi O-P, Nevanlinna H: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002, 71: 432-438. 10.1086/341943.CrossRefPubMedPubMedCentral
Metadaten
Titel
Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk
verfasst von
Jenny Varley
Daniel A Haber
Publikationsdatum
01.06.2003
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 3/2003
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr582

Weitere Artikel der Ausgabe 3/2003

Breast Cancer Research 3/2003 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.